Your browser doesn't support javascript.
loading
Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
Evans, Elizabeth A; Stopka, Thomas J; Pivovarova, Ekaterina; Murphy, Sean M; Taxman, Faye S; Ferguson, Warren J; Bernson, Dana; Santelices, Claudia; McCollister, Kathryn E; Hoskinson, Randall; Lincoln, Thomas; Friedmann, Peter D.
Afiliação
  • Evans EA; Department of Health Promotion and Policy, School of Public Health and Health Sciences, University of Massachusetts Amherst, 312 Arnold House, 715 North Pleasant Street, Amherst, MA 01003, United States of America. Electronic address: eaevans@umass.edu.
  • Stopka TJ; Department of Public Health and Community Medicine, Tufts University School of Medicine, 136 Harrison Avenue, Boston, MA 02111, United States of America.
  • Pivovarova E; Department of Psychiatry, University of Massachusetts Medical School and Massachusetts Center of Excellence for Specialty Courts, Worcester, MA, United States of America; Department of Family Medicine and Community Health, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester,
  • Murphy SM; Department of Population Health Sciences, Weill Cornell Medical College, 425 East 61st Street, Suite 301, New York, NY, United States of America. Electronic address: smm2010@med.cornell.edu.
  • Taxman FS; Center for Advancing Correctional Excellence, George Mason University, 4087 University Drive, 4100, MSN6D3, Fairfax, VA 22030, United States of America.
  • Ferguson WJ; Department of Family Medicine and Community Health, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, United States of America. Electronic address: warren.ferguson@umassmemorial.org.
  • Bernson D; Massachusetts Department of Public Health, 250 Washington Street, Boston, MA 02108, United States of America.
  • Santelices C; Urban Health Research and Practice, Northeastern University, Boston, MA, United States of America.
  • McCollister KE; Soffer Clinical Research Center, Department of Public Health Sciences, University of Miami Miller School of Medicine, 1120 NW 14(th) Street, Suite 1019, Miami, FL 33136, United States of America. Electronic address: kmccolli@miami.edu.
  • Hoskinson R; University of Massachusetts Medical School - Baystate, Springfield, MA, United States of America.
  • Lincoln T; University of Massachusetts Medical School - Baystate, Springfield, MA, United States of America.
  • Friedmann PD; University of Massachusetts Medical School - Baystate, Springfield, MA, United States of America. Electronic address: peter.friedmannmd@baystatehealth.org.
J Subst Abuse Treat ; 128: 108275, 2021 09.
Article em En | MEDLINE | ID: mdl-33483222
ABSTRACT
A major driver of the U.S. opioid crisis is limited access to effective medications for opioid use disorder (MOUD) that reduce overdose risks. Traditionally, jails and prisons in the U.S. have not initiated or maintained MOUD for incarcerated individuals with OUD prior to their return to the community, which places them at high risk for fatal overdose. A 2018 law (Chapter 208) made Massachusetts (MA) the first state to mandate that five county jails deliver all FDA-approved MOUDs (naltrexone [NTX], buprenorphine [BUP], and methadone). Chapter 208 established a 4-year pilot program to expand access to all FDA-approved forms of MOUD at five jails, with two more MA jails voluntarily joining this initiative. The law stipulates that MOUD be continued for individuals receiving it prior to detention and be initiated prior to release among sentenced individuals where appropriate. The jails must also facilitate continuation of MOUD in the community on release. The Massachusetts Justice Community Opioid Innovation Network (MassJCOIN) partnered with these seven diverse jails, the MA Department of Public Health, and community treatment providers to conduct a Type 1 hybrid effectiveness-implementation study of Chapter 208. We will (1) Perform a longitudinal treatment outcome study among incarcerated individuals with OUD who receive NTX, BUP, methadone, or no MOUD in jail to examine postrelease MOUD initiation, engagement, and retention, as well as fatal and nonfatal opioid overdose and recidivism; (2) Conduct an implementation study to understand systemic and contextual factors that facilitate and impede delivery of MOUDs in jail and community care coordination, and strategies that optimize MOUD delivery in jail and for coordinating care with community partners; (3) Calculate the cost to the correctional system of implementing MOUD in jail, and conduct an economic evaluation from state policy-maker and societal perspectives to compare the value of MOUD prior to release from jail to no MOUD among matched controls. MassJCOIN made significant progress during its first six months until the COVID-19 pandemic began in March 2020. Participating jail sites restricted access for nonessential personnel, established other COVID-19 mitigation policies, and modified MOUD programming. MassJCOIN adapted research activities to this new reality in an effort to document and account for the impacts of COVID-19 in relation to each aim. The goal remains to produce findings with direct implications for policy and practice for OUD in criminal justice settings.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 4_TD / 8_ODS3_consumo_sustancias_psicoactivas Base de dados: MEDLINE Assunto principal: Buprenorfina / COVID-19 / Transtornos Relacionados ao Uso de Opioides Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: J Subst Abuse Treat Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 2_ODS3 / 4_TD / 8_ODS3_consumo_sustancias_psicoactivas Base de dados: MEDLINE Assunto principal: Buprenorfina / COVID-19 / Transtornos Relacionados ao Uso de Opioides Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: J Subst Abuse Treat Ano de publicação: 2021 Tipo de documento: Article